Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Okla. Plan B restriction blocked; CRN knocks disease claims via NAD; Facebook testimonial stings Vibrant Life

This article was originally published in The Tan Sheet

Executive Summary

Oklahoma judge blocks Plan B restrictions; CRN challenges disease claims via NAD; Lonza backs Alomune claims, ERSP says; Facebook testimonial prompts Vibrant Life warning; Rx adulterant recalls, alerts; and Codex adopts 11 nutrient reference values;.

You may also be interested in...

Firms Navigate Social Media Safely Following Loss Of Facebook Protection

Several drug companies may have shuttered their Facebook pages prematurely in August after the social networking site revoked their exclusive privilege to block consumer comments on their walls.

International Panel’s Nutrient Value Guideline May Boost Supplement Exports

Dietary supplement firms soon could export products internationally without having to reformulate to accommodate local nutrient value regulations.

Veru Hopes To Position Enobosarm As Muscle-Protective In Weight-Loss Therapy

A selective androgen receptor modulator also being studied in metastatic breast cancer, enobosarm might offer potential as add-on therapy to GLP-1 agonists prescribed for weight loss, the Miami biotech asserts.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts